Hostname: page-component-cb9f654ff-kl2l2 Total loading time: 0 Render date: 2025-08-27T18:48:45.992Z Has data issue: false hasContentIssue false
  • English
  • Français

Improving monitoring for metabolic syndrome using audit

Published online by Cambridge University Press:  13 June 2014

Alan Murtagh ,
Radu Petrovici ,
Wendy Wong ,
Curtis Obadan ,
Olufemi Solanke ,
Emmanuel Nnabuchi  and
Kevin Kilbride
Alan Murtagh
Affiliation:
HSE Northern Area, St. Brendan's Hospital, Dublin
Radu Petrovici
Affiliation:
HSE Northern Area, St. Brendan's Hospital, Dublin
Wendy Wong
Affiliation:
St Patrick's Hospital, Dublin
Curtis Obadan
Affiliation:
Department of Psychiatry, Our Lady's Hospital, Navan
Olufemi Solanke
Affiliation:
Community Drug & Alcohol Services, Worthing, East Sussex
Emmanuel Nnabuchi
Affiliation:
HSE Northern Area, St. Brendan's Hospital, Dublin
Kevin Kilbride*
Affiliation:
HSE Northern Area, St. Brendan's Hospital, Dublin 7
*
*Correspondence Email: kevin.kilbride1@hse.ie
Get access Rights & Permissions [Opens in a new window]

Extract

Audit has been defined as “a quality improvement process that seeks to improve patient care and outcome, through systematic review of care and comparison with explicit criteria, followed by the implementation of change”. As of May 2011, under the Medical Practitioners Act 2007, doctors are legally obliged to join in professional competence schemes, following requirements set by the Medical Council. These include the obligation for doctors to conduct one clinical audit per year. In Ireland and elsewhere, audit provides an opportunity for services to create an “environment in which clinical care will flourish”.

Information

Type
CPD
Information
Irish Journal of Psychological Medicine , Volume 28 , Issue 3 , September 2011 , pp. i - iv
Copyright
Copyright © Cambridge University Press 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.A First Class Service: Quality in the new NHS. London: Department of Health 1998.Google Scholar
2.Royal College of Psychiatrists. Clinical Audit Resources. Clinical Audit Step-by-step Guide (Chapter 2). www.rcpsych.ac.uk/pdf/clinauditChap2.pdfGoogle Scholar
3.Osby, U, Brandt, L, Correia, Net al.Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58: 844–850.CrossRefGoogle ScholarPubMed
4.Hennekens, CH, Hennekens, AR, Hollar, D, Casey, DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150: 1115–1121.CrossRefGoogle ScholarPubMed
5.Mottillo, S, Filion, KB, Genest, Jet al.The metabolic syndrome and cardiovascular risk - a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56(14): 1113–1132.CrossRefGoogle ScholarPubMed
6.Colton, CW, Manderscheid, RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006; 3: A42Google ScholarPubMed
7.Ford, ES, Giles, WH, Dietz, WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–359.CrossRefGoogle ScholarPubMed
8.Correll, CU, Druss, BG, Lombardo, Iet al.Findings of a U.S. national cardiometabolic screening program among 10,084 psychiatric outpatients. Psychiatr Serv 2010; 61: 892–898.CrossRefGoogle Scholar
9.Ryan, MC, Collins, P, Thakore, JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160: 284–289.CrossRefGoogle ScholarPubMed
10.Thakore, JH, Mann, JN, Vlahos, Iet al.Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002; 26: 137–141.CrossRefGoogle ScholarPubMed
11.Vancampfort, D, Knapen, J, Probst, Met al.Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia. Psychiatry Res 2010; 177: 271–279.CrossRefGoogle Scholar
12.Strassnig, M, Brar, JS, Ganguli, R. Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull 2003; 29: 393–397.CrossRefGoogle ScholarPubMed
13.Bobes, J, Arango, C, Garcia-Garcia, M, Rejas, J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr Res 2010; 119: 101–109.CrossRefGoogle ScholarPubMed
14.Jin, H, Folsom, D, Sasaki, Aet al.Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. Schizophr Res 2011; 125(2): 295–299.CrossRefGoogle ScholarPubMed
15.Marder, SR, Essock, SM, Miller, ALet al.Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334–1349.CrossRefGoogle ScholarPubMed
16.Khatana, SAM, Kane, J, Taveira, THet al.Monitoring and Prevalence Rates of Metabolic Syndrome in Military Veterans with Serious Mental Illness. 2011 PLoSONE6(4):e19298.doi: 10.1371/journal. pone.0019298CrossRefGoogle ScholarPubMed
17.Holt, RIG, Peveler, RC, Byrne, CD. Schizophrenia, the metabolic syndrome and diabetes. Diabet Med 2004; 21: 515–523.CrossRefGoogle ScholarPubMed
18.Lambert, TJR, Chapman, LH, on behalf of the Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181: 544–548.CrossRefGoogle ScholarPubMed
19.Antai-Otong, D. Metabolic effects associated with atypical antipsychotic medications. Perspect Psychiatr Care 2004; 40: 70–72.CrossRefGoogle ScholarPubMed
20.American Diabetes Association and American Psychiatric Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596–601.CrossRefGoogle Scholar
21.Taylor, D, Young, C, Esop, R, et al.Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004; 185: 152–156.CrossRefGoogle ScholarPubMed
22.Jennex, A, Gardner, DM. Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: a controlled study. Can J Psychiatry 2008; 53: 34–42.CrossRefGoogle ScholarPubMed
23.Morrato, EH, Newcomer, JW, Allen, RR, Valuck, RJ. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry 2008; 69: 316–322.CrossRefGoogle ScholarPubMed
24. International Diabetes Federation. The IDF Consensus worldwide definition of the Metabolic Syndrome; 2006.Google Scholar
25.Grundy, SM, Brewer, HB, Cleeman, JLet al.Definition of the metabolic syndrome. Circulation 2004; 109: 433–438.CrossRefGoogle Scholar
26.Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596–601.CrossRefGoogle Scholar
27.CKS Schizophrenia (PRODIGY Guidance). Clinical Knowledge Service; 2007 www.cks.library.nhs.uk/schizophrenia (Accessed June 2011)Google Scholar